Simon Patterson Joins GoodRx Board of Directors

Rhea-AI Summary

GoodRx (Nasdaq: GDRX) has appointed Simon Patterson to its Board of Directors. Patterson, who leads EMEA operations for Silver Lake, a technology investment firm, brings extensive experience in tech, strategy, and management. He has held board positions at companies like Dell Technologies and Skype. Patterson's expertise is expected to assist GoodRx in scaling its business and making prescription medications more affordable. He will also join the Board's Nominating and Corporate Governance Committee.

Positive

• Simon Patterson's appointment brings significant tech, strategy, and management experience to GoodRx.
• Patterson's background includes leadership roles at Silver Lake and board positions at major firms like Dell Technologies and Skype.
• GoodRx aims to leverage Patterson's expertise to scale its business and enhance medication affordability.
• Patterson’s addition to the Nominating and Corporate Governance Committee could strengthen GoodRx’s governance.

Negative

• No immediate financial or business growth metrics were disclosed with Patterson's appointment.
• The announcement lacks specific details on how Patterson's involvement will directly impact GoodRx’s revenue or stock performance.

Former Dell Technologies and Skype Board member brings decades of tech, strategy and management experience to GoodRx

SANTA MONICA, Calif.--(BUSINESS WIRE)-- GoodRx (Nasdaq: GDRX), the leading destination for prescription savings in the U.S., today announced the election of Simon Patterson to its Board of Directors. Currently leading EMEA operations for the technology investment firm Silver Lake, Mr. Patterson brings to GoodRx decades of technology, strategy and management experience. Mr. Patterson also serves on the boards of IVC Evidensia, New Zealand Rugby Commercial, RAC, and ZPG, and previously served on the boards of Cegid, Dell Technologies, FlixBus, Gerson Lehrman Group, Intelsat, MultiPlan and Skype.

“We believe Mr. Patterson’s significant expertise in finance and management, formed by his extensive experience operating, advising and investing in high-growth technology companies, will be a strong asset to GoodRx,” said Trevor Bezdek, GoodRx co-founder and Chairman of the Board. “We look forward to benefiting from his business acumen as we scale our business to make prescription medications more accessible and affordable for all Americans.”

Mr. Patterson has also joined the Board’s Nominating and Corporate Governance Committee.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save nearly $75 billion and is one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at https://investors.goodrx.com. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx’s website regularly for important information, in addition to following GoodRx’s press releases, filings with the Securities and Exchange Commission (the “SEC”) and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx’s website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the scaling of our business, benefits to consumers from our offerings and anticipated contributions from Simon Patterson in his directorship. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption “Risk Factors” in GoodRx’s Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240530591769/en/

Investor Contact

ir@goodrx.com



Media Contact

press@goodrx.com

Source: GoodRx

FAQ

What is the significance of Simon Patterson joining GoodRx's Board of Directors?

Simon Patterson's extensive experience in technology, strategy, and management is expected to help GoodRx scale its business and make medications more affordable.

What companies has Simon Patterson been involved with before joining GoodRx?

Patterson has held board positions at companies such as Dell Technologies, Skype, Cegid, FlixBus, and Intelsat.

What role will Simon Patterson play in GoodRx's governance?

In addition to joining the Board of Directors, Patterson will serve on GoodRx’s Nominating and Corporate Governance Committee.

How might Simon Patterson's appointment affect GoodRx's stock price?

While Patterson's expertise could benefit GoodRx, the press release does not provide specific financial impact details.

What expertise does Simon Patterson bring to GoodRx?

Patterson brings decades of experience in technology, finance, strategy, and management from leading high-growth technology companies.